Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234

Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234

Purpose: An evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing TP53 missense mutations as high-risk, associated with poor outcomes, or low-risk, with similar outcomes as TP53 wild-type...

Full description

Bibliographic Details
Main Authors: Chieko Michikawa, DDS, PhD, Pedro A. Torres-Saavedra, PhD, Natalie L. Silver, MD, MS, Paul M. Harari, MD, Merrill S. Kies, MD, David I. Rosenthal, MD, Quynh-Thu Le, MD, Richard C. Jordan, DDS, PhD, Dzifa Y. Duose, PhD, Saradhi Mallampati, DVM, PhD, Sanchit Trivedi, MS, Rajyalakshmi Luthra, PhD, Ignacio I. Wistuba, MD, Abdullah A. Osman, PhD, Olivier Lichtarge, MD, PhD, Robert L. Foote, MD, Upendra Parvathaneni, MBBS, D. Neil Hayes, MD, MPH, Curtis R. Pickering, PhD, Jeffrey N. Myers, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109422000963

Internet

http://www.sciencedirect.com/science/article/pii/S2452109422000963

Similar Items